ClinicalTrials.gg
RecruitingNCT06712810Updated Oct 10, 2025

Q702 for the Treatment of Patients With Hematologic Malignancies

A Phase 1 interventional study of Axl/Mer/CSF1R Inhibitor Q702 and Biospecimen Collection in Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma and Malignant Histiocytosis, sponsored by Mayo Clinic. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by Mayo Clinic · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in Lymphoma, T-Cell with a site in United States — 34 open to participants now, 50 under way, 2 of them phase 3. Lymphoma, T-Cell · United States.

Planned enrollment
60th of 166
46 · median 33
Started
2025
with 5 others
Phase 1
69 of 173
11 open now
Primary completion
2030-09
later than 44 of 49 live
Registered
161st of 173
by date
Lead sponsor
7 of 173
Mayo Clinic

Among the 173 studies in Lymphoma, T-Cell with a site in United States, this one is the 60th largest by planned enrollment of the 166 interventional ones that give a count, is one of 6 that started in 2025, is one of 69 in phase 1, reaches primary completion later than 44 of the 49 other live ones, and was the 161st registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

34 of the 173 studies in Lymphoma, T-Cell with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Lymphoma, T-Cell studies recruiting now, 40 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Lymphoma, T-Cell with a site in United States, or all of them as a file.
02

Study summary

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

Read the detailed description

PRIMARY OBJECTIVES:

I. Establish the highest dose of Q702 tested that has acceptable tolerability and safety. (Dose determination) II. Safety and overall response assessment in patients with hematologic malignancies who have been treated with Q702. (Dose expansion)

SECONDARY OBJECTIVES:

I. Assessment of progression-free survival and overall survival. II. Safety and tolerability of Q702.

EXPLORATORY OBJECTIVE:

I. Improvement of quality of life (QOL) assessed by using the Patient-Reported Outcomes Measurement Information System (PROMIS) tool compared to pretreatment values.

CORRELATIVE OBJECTIVES:

I. Programmed Death-Ligand 1 (PD-L1), Colony stimulating factor 1 receptor (CSF1R) expression of tumor before and after treatment.

II. M2 macrophage population assessed through flow cytometry by using peripheral blood before and after treatment.

III. Serum cytokine interferon gamma, Interleukin (IL)-1b, IL-6, IL-4, IL-10, IL-13, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) before and after each cycle of therapy.

IV. Assessment of inflammatory markers before and after treatment with Q702. V. Assessment of cluster of differentiation 4 (CD4)/cluster of differentiation 8 (CD8) infiltration in the tumor involvement before, during, and after treatment with Q702.

OUTLINE: This is a dose-escalation study of Q702 followed by a dose-expansion study.

Patients receive Q702 orally (PO) daily (QD) on days 1-7 and 15-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients who have not progressed/relapsed may continue on therapy at their current dose at medical doctor (MD)/patient discretion for an additional 6 cycles. Patients undergo blood and urine sample collection and may undergo positron emission tomography (PET) scan/computed tomography (CT) scan or magnetic resonance imaging (MRI) and bone marrow aspiration and biopsy throughout the study.

After completion of study treatment, patients are followed up every 6 months and at progressive disease for 2 years.

03

Conditions studied

  • Hematopoietic and Lymphatic System Neoplasm
  • Histiocytic Sarcoma
  • Malignant Histiocytosis
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Recurrent Chronic Lymphocytic Leukemia
  • Recurrent Chronic Myelomonocytic Leukemia
  • Recurrent Follicular Lymphoma
  • Recurrent Langerhans Cell Histiocytosis
  • Recurrent Lymphoplasmacytic Lymphoma
  • Recurrent Myelodysplastic Syndrome
  • Recurrent Myelofibrosis
  • Recurrent Small Lymphocytic Lymphoma
  • Recurrent Waldenstrom Macroglobulinemia
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Chronic Myelomonocytic Leukemia
  • Refractory Erdheim-Chester Disease
  • Refractory Follicular Lymphoma
  • Refractory Langerhans Cell Histiocytosis
  • Refractory Lymphoplasmacytic Lymphoma
  • Refractory Myelodysplastic Syndrome
  • Refractory Myelofibrosis
  • Refractory Small Lymphocytic Lymphoma
  • Refractory Waldenstrom Macroglobulinemia
  • Rosai-Dorfman-Destombes Disease
  • Primary Central Nervous System Lymphoma
  • Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Recurrent Erdheim-Chester Disease
  • Recurrent Fibroblastic Reticular Cell Sarcoma
  • Recurrent Histiocytic Sarcoma
  • Recurrent Interdigitating Dendritic Cell Sarcoma
  • Recurrent Rosai-Dorfman-Destombes Disease
  • Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Refractory Fibroblastic Reticular Cell Sarcoma
  • Refractory Histiocytic Sarcoma
  • Refractory Interdigitating Dendritic Cell Sarcoma
  • Refractory Rosai-Dorfman-Destombes Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PRE-REGISTRATION: Age ≥ 18 years
  • PRE-REGISTRATION: Not eligible for or have failed therapies with established benefits, at the discretion of the treating physician
  • PRE-REGISTRATION: Patients must meet one of the following criteria:

    • patients with Erdheim-Chester disease, Langerhans histiocytosis, histiocytic sarcoma, or other malignant histiocytosis without activating alterations in v-Raf murine sarcoma viral oncogene homolog B (BRAF) or Mitogen-activated protein kinase kinase (MAP2K) oncogenes who have progressed after of therapy.

      • Note: Relapsed is defined as a relapse that occurred after having a response to the last therapy at any point during the treatment. Refractory is no response (stable disease or progressive disease while on therapy) to a given treatment at least after 1 month of being on the given treatment.
    • Newly diagnosed patients with Rosai-Dorfman disease without activating alterations in MAP2K oncogenes.
    • Relapsed/refractory patients with Rosai-Dorfman disease and an activating mitogen-activated protein kinase (MAPK) pathway alteration who have failed prior treatment with cobimetinib.
    • Relapsed/refractory patients with Erdheim-Chester disease or Langerhans histiocytosis who have received vemurafenib for BRAF V600E mutated disease or cobimetinib for disease with activating MAP2K alterations.
    • Patients with Erdheim-Chester disease, Rosai-Dorfman disease, Langerhans histiocytosis, histiocytic sarcoma, or another malignant histiocytosis who cannot tolerate or have a to BRAF or MEK inhibitors or those who cannot have reliable access to these inhibitors due to financial restraints or geographic location or initiation of BRAF or mitogen-activated protein kinase kinase (MEK) inhibitors is futile based on the genomic alterations or the discretion of treating physician.
    • Relapsed/refractory higher risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or myelofibrosis (MF).

      • Note: MF patients must have failed ≥ 1 of the 4 Food and Drug Administration (FDA)-approved Janus kinase (JAK) Inhibitors for MF (i.e. ruxolitinib, fedratinib, pacritinib, momelotinib) to be eligible. MDS and CMML patients must have failed hypomethylating agent-based therapy, if eligible.
      • Note: Higher risk is defined as intermediate or higher risk by international prognostic scoring system (IPSS-R) or moderate high or higher risk as per molecular internal prognostic scoring system (IPSS-M).
    • T cell lymphoma (peripheral and cutaneous), or mantle cell lymphomas. Patients must have failed ≥ 2 lines of therapy.
    • Primary central nervous system (CNS) lymphoma who has failed ≥ 2 lines of therapy.
    • Relapsed or refractory follicular lymphoma; or Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. Must have failed ≥ 2 lines of therapy.
    • Patients with Waldenström macroglobulinemia who have received or are not eligible for a Bruton tyrosine kinase (BTK)-inhibitor therapy.
    • Relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have failed ≥ 2 lines of therapy and have been treated with at least one prior line of a BTK inhibitor and/or a B-cell lymphoma 2 (BCL2) inhibitor. Need documented CLL/SLL requiring treatment according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines 2018.

      • NOTE: Use of oral up to 20 mg of daily will be allowed for patients who are discontinuing BTK inhibitors just prior to the registration. This is not mandatory and should be done at the discretion of patient's treating physician.

        • Note: All patients in the above disease groups may be on corticosteroids at the investigator's discretion
  • PRE-REGISTRATION: Histopathological or cytological confirmation of diseases
  • PRE-REGISTRATION: Willingness to provide mandatory blood, bone marrow aspirate, saliva, and tissue specimens for correlative research, as applicable to the disease site
  • PRE-REGISTRATION: Ability to swallow pills
  • REGISTRATION: (ECOG) performance status (PS) 0, 1, or 2
  • REGISTRATION: of ≥ 3 months
  • REGISTRATION: Measurable or assessable disease:

    • For histiocytic neoplasms and lymphoma- is defined as measurable by CT (dedicated CT or the CT portion of a PET/CT) or MRI: To be considered measurable, there must be at least one lesion that has a single diameter of ≥ 1.5 cm for non-CNS disease. For CNS involved disease, MRI confirmation with any size would be appropriate.

      • NOTE: Skin lesions can be used if the area is ≥ 1.5 cm in at least one diameter and photographed with a ruler. Patients with assessable disease by PET/CT are also eligible as long as the assessable disease is proven lymphoma or histiocytic/dendritic cell neoplasms.
    • For all other eligible diseases listed-N/A
  • REGISTRATION: ≥ 8.0 g/dL (obtained ≤ 14 days prior to registration)
  • REGISTRATION: (ANC) ≥ 1.0 x 10\^9/L (obtained ≤ 14 days prior to registration)
  • REGISTRATION: count ≥ 80 x 10\^9/L (obtained ≤ 14 days prior to registration)
  • REGISTRATION: White blood cell (WBC) ≥ 2.5 x 10\^9/L (obtained ≤ 14 days prior to registration)
  • REGISTRATION: Total ≤ 1.5 x (ULN) (obtained ≤ 14 days prior to registration)
  • REGISTRATION: (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement) (obtained ≤ 14 days prior to registration)
  • REGISTRATION: Serum creatinine of ≤ 1.5 x ULN and calculated of ≥ 50 mL/min using the Cockcroft-Gault formula (obtained ≤ 14 days prior to registration)
  • REGISTRATION: Negative urine or serum pregnancy test done ≤ 7 days prior to registration, for persons of only
  • REGISTRATION: Sexually active patients and their partners must use an effective method of associated with a low failure rate prior to study entry and for the duration of study participation and for at least 3 months after the last dose of study drug.

    • Note: The following are considered effective contraceptives: oral contraceptive pill; condom plus spermicide; diaphragm plus spermicide; patient or partner surgically sterile; patient or partner more than 2 years ; or injectable or implantable agent/device
  • REGISTRATION: Provide written
  • REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance
  • REGISTRATION: Willing to return to the enrolling institution for follow-up (during the Active Monitoring Phase of the study).

Exclusion criteria

Exclusion Criteria:

  • PRE-REGISTRATION: Myeloproliferative neoplasm (MPN) patients with known active and/or carcinomatous meningitis.

    • Note: Histiocytosis and lymphoma patients who are on are allowed to enroll
  • REGISTRATION: Any of the following because this study involves an agent whose genotoxic, mutagenic and teratogenic effect on the developing fetus and newborn are unknown:

    • Pregnant persons
    • Nursing persons
    • Persons of (and persons able to father a child) who are unwilling to employ adequate
  • REGISTRATION: Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure ≤ 6 months prior to registration
  • REGISTRATION: interval (using Fridericia's correction formula) (QTcF) of > 470 msec
  • REGISTRATION: Known active infection with (HIV), Human T-lymphotropic virus 1 (HTLV-1), virus (HBV), or virus (HCV):

    • Active infection with (HIV) and \< 350 μL.
    • Patients with a detectable HIV viral load and not on antiretroviral therapy (ART) for ≥ 4 weeks.
    • Exceptions:

      • Patients with a history of hepatitis B or C are allowed if HBV deoxyribonucleic acid (DNA) or HCV ribonucleic acid (RNA) are undetectable.
      • Patients with active HIV infection and CD4+ T-cell count ≥ 350 μL who are on active antiretroviral treatment
  • REGISTRATION: Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • REGISTRATION: Concomitant use of strong inhibitors and inducers of CYP1A2, CYP2C19, CYP2D6, and strong inhibitors and inducers of within five half-lives of the active drug prior to registration and throughout the trial.

    • Note: Strong inhibitors and inducers of CYP3A4 should be discontinued for five half-lives of the active drug prior to starting study drug and avoided throughout the trial
  • REGISTRATION: Concomitant use of any herbal supplements.

    • Note: Supplements taken prior to starting study drug should be discussed with the Principal Investigator as varied may be clinically indicated and necessary
  • REGISTRATION: Any of the following prior therapies used as primary cancer treatment:

    • Targeted therapeutics other than monoclonal antibodies (e.g., kinases inhibitors) ≤ 2 weeks prior to registration.
    • Monoclonal antibodies ≤ 6 weeks, or ≥ 5 half-life, whichever is shorter, prior to registration.
    • Chemotherapy ≤ 4 weeks prior to registration (6 weeks for nitrosoureas or Mitomycin C.
    • Surgery ≤ 4 weeks prior to registration
    • Any investigational therapy ≤ 4 weeks prior to registration
    • Radiation therapy ≤ 4 weeks prior to registration

      • Exceptions:

        • Palliative radiation therapy ≥ 2 weeks prior to registration for control of tumor mass related symptoms (e.g., pain control from a discrete bone ) allowed, unless the radiation field includes organs for which the radiation therapy could result in certain direct organ toxicities (e.g., radiation induced esophagitis), which could complicate the interpretation of the Q702 safety profile.
        • Radiation induced toxicities which could interfere with the interpretation of the Q702 safety profile should recover to ≤ grade 1 before registration.
        • Patients receiving palliative radiation intended to reduce the risk of a potential pathological fracture should be allowed ≥ 4 weeks from the last radiation therapy treatment to recover from any radiation induced toxicity and to allow for an adequate period of observation relative to the potential risk of a pathological fracture
  • REGISTRATION: Failure to recover from acute, reversible effects of prior therapy to ≤ grade 1 or patient baseline prior to registration.

    • NOTE: Patient with chronic effects such as neuropathy, fatigue, keratitis/keratopathy, anorexia, etc. are allowed
  • REGISTRATION: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • REGISTRATION: Active retinal pigment epithelium (RPE)/photoreceptor disorders such as retinitis pigmentosa, cone-rod dystrophies, Bests dystrophy, Stargardt disease (STGD), macular degeneration, retinal detachment, and opaque cornea. Exceptions:

    • Mild blurry vision, either age-related or due to ocular or systemic disorder (e.g., diabetes, dry eyes, cataracts, uncorrected refraction abnormality) may be allowed at the discretion of the ophthalmologist if deemed as not constituting evidence of pre-existing retinopathy (e.g., severe nonproliferative or proliferative diabetes retinopathy) or a condition with the potential to cause a predisposition to drug-induced retinopathy. [e.g., severe retinal vascular disease with scattered intraretinal hemorrhages, cotton wool-spots and intraretinal microvascular abnormalities (IRMA)]
    • Patients with only one assessable eye and no evidence of pre-existing retinopathy may be allowed at the discretion of the principal investigator
  • REGISTRATION: Active second requiring treatment that would interfere with the assessment of the response of the primary cancer or interpretation of the safety of this protocol therapy
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Treatment (Q702)

    Patients receive Q702 PO QD on days 1-7 and 15-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients who have not progressed/relapsed may continue on therapy at their current dose at MD/patient discretion for an additional 6 cycles. Patients undergo blood and urine sample collection and may undergo PET scan/CT scan or MRI and bone marrow aspiration and biopsy throughout the study.

    Drug: Axl/Mer/CSF1R Inhibitor Q702 · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Other: Survey Administration

Interventions

  • DrugAxl/Mer/CSF1R Inhibitor Q702

    Drug page: AdrixetinibStudies of AdrixetinibAdrixetinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702, Q 702, Q-702, Q702, RTK Inhibitor Q702

  • ProcedureBiospecimen Collection

    Undergo blood and urine sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow biopsy and aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy and aspiration

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • ProcedurePositron Emission Tomography

    Undergo PET scan

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT

  • OtherSurvey Administration

    Ancillary study

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity

    Up to completion of the first cycle (cycle length= 28 days)

    Time frame: Up to 3 years

  2. Overall response rate

    Exact binomial 95% confidence intervals for the true rate of overall response will be calculated.

    Time frame: Up to 3 years

Secondary outcomes

  1. Progression free survival (PFS)

    PFS is defined as is defined as the time from registration to progression or death due to any cause

    Time frame: Up to 3 years

  2. Overall survival (OS)

    Overall survival (OS) is defined as the time from registration to death due to any cause.

    Time frame: Up to 3 years

  3. Incidence of adverse events

    The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.

    Time frame: Up to 3 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Sep 2030, 60 months after the start.

Of 40 non-industry phase 1 interventional studies under Lymphoma, T-Cell, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 60 months is above that.

Counting every sponsor, half of 59 studies reached it within 57 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 2, 2024
StartActual
Aug 27, 2025
Primary completionEst.
Sep 15, 2030
CompletionEst.
Sep 15, 2030
Last update
Oct 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06712810
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Aug 27, 2025
Primary completion
Sep 15, 2030 (estimated)
Completion
Sep 15, 2030 (estimated)
Last update
Oct 10, 2025

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Jithma P. Abeykoon, MD
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adrixetinib

Start the discussion